<info type="SequenceVariant">Two novel mutations</info> of the <info type="GeneOrGeneProduct">TSH-beta subunit gene</info> underlying <info type="DiseaseOrPhenotypicFeature">congenital central hypothyroidism</info> undetectable in neonatal <info type="GeneOrGeneProduct">TSH</info> screening.

<info type="DiseaseOrPhenotypicFeature">CONTEXT</info>: Patients with <info type="GeneOrGeneProduct">TSH-beta subunit</info> defects and <info type="DiseaseOrPhenotypicFeature">congenital hypothyroidism</info> are missed by <info type="GeneOrGeneProduct">TSH</info>-based neonatal screening. <info type="DiseaseOrPhenotypicFeature">OBJECTIVE</info>: Our objective was to report the molecular consequences of a <info type="SequenceVariant">novel splice-junction mutation</info> and a <info type="SequenceVariant">novel missense mutation</info> in the <info type="GeneOrGeneProduct">TSH-beta subunit gene</info> found in two patients with <info type="DiseaseOrPhenotypicFeature">congenital central hypothyroidism</info> and <info type="DiseaseOrPhenotypicFeature">conventional treatment-resistant anemia</info>. <info type="DiseaseOrPhenotypicFeature">RESULTS</info>: Patient 1 had a <info type="SequenceVariant">homozygous G to A nucleotide change</info> at the <info type="SequenceVariant">5' donor splice site</info> of <info type="GeneOrGeneProduct">exon/intron 2</info>. This resulted in a <info type="SequenceVariant">silent change</info> at codon 34 of the mature protein. In vitro splicing assays showed that the mutant minigene dramatically affected <info type="GeneOrGeneProduct">pre-mRNA</info> processing, causing <info type="GeneOrGeneProduct">exon 2</info> to be completely skipped. The putative product from a new out-of-frame translational start point in <info type="GeneOrGeneProduct">exon 3</info> is expected to yield a <info type="SequenceVariant">nonsense 25-amino-acid peptide</info>. In patient 2, <info type="GeneOrGeneProduct">sequence analysis</info> revealed a <info type="SequenceVariant">compound heterozygosis</info> for the already reported <info type="SequenceVariant">313delT (C105Vfs114X)</info> mutation and for a second <info type="SequenceVariant">novel mutation</info> in <info type="GeneOrGeneProduct">exon 3</info>, substituting <info type="ChemicalEntity">G</info> for <info type="ChemicalEntity">A</info> at cDNA nucleotide position 323, resulting in a <info type="SequenceVariant">C88Y change</info>. This <info type="GeneOrGeneProduct">cysteine residue</info> is conserved among all <info type="GeneOrGeneProduct">dimeric pituitary</info> and <info type="GeneOrGeneProduct">placental glycoprotein hormone-beta subunits</info>. Data from <info type="GeneOrGeneProduct">in silico analysis</info> confirmed that the <info type="SequenceVariant">C88Y mutation</info> would affect subunit conformation. Indeed, two different <info type="GeneOrGeneProduct">bioinformatics approaches</info>, <info type="GeneOrGeneProduct">PolyPhen</info> and <info type="GeneOrGeneProduct">SIFT analysis</info>, predicted <info type="SequenceVariant">C88Y</info> to be a damaging substitution. <info type="DiseaseOrPhenotypicFeature">CONCLUSIONS</info>: In isolated <info type="DiseaseOrPhenotypicFeature">TSH deficiency</info>, the exact molecular diagnosis is mandatory for diagnosis of isolated <info type="DiseaseOrPhenotypicFeature">pituitary deficiency</info>, delineation of prognosis, and genetic counseling. Moreover, diagnosis of <info type="DiseaseOrPhenotypicFeature">central hypothyroidism</info> should be considered in the face of severe <info type="DiseaseOrPhenotypicFeature">infant anemia</info> of uncertain etiology.